Lymphoma

A phase 2 study reveals impactful objective response rates with manageable adverse events in patients with relapsed/refractory follicular lymphoma treated with odronextamab.

Denileukin diftitox received FDA approval to treat relapsed/refractory cutaneous T-cell lymphoma previously treated with at least 1 systemic therapy.

The monitoring period after CAR T-cell therapy may be safe if shortened due to the lower incidence of ICANS and CRS 2 weeks after treatment in patients with DLBCL.

Durable complete responses were observed in patients with TP52-mutated mantle cell lymphoma treated with ibrutinib plus venetoclax.

Adding brentuximab vedotin to lenalidomide/rituximab results in a stronger overall survival benefit compared with lenalidomide/rituximab alone in relapsed/refractory diffuse large B-cell lymphoma.

Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.

Adding ibrutinib to chemoimmunotherapy induction with autologous stem-cell transplantation improves failure-free survival rates in younger patients with mantle cell lymphoma.

Throughout June, the FDA approved drugs for the treatment of diseases including myelodysplastic syndrome, thyroid cancer, endometrial cancer, colorectal cancer, and follicular lymphoma.

An accelerated approval has been granted by the FDA to epcoritamab-bysp (Epkinly) for adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy.

The administration of CAR T-cell therapy in an outpatient setting was deemed feasible and safe for patients with relapsed/refractory non-Hodgkin lymphoma.

Treatment with acalabrutinib and bendamustine/rituximab in the frontline setting improved progression-free survival in older patients with MCL.

Glofitamab-gxbm plus gemcitabine and oxaliplatin significantly improved survival in relapsed/refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplant.

A subgroup analysis of the TRANSCEND NHL 001 trial demonstrated that liso-cel may be more effective in earlier lines of treatment for patients with mantle cell lymphoma.

Tucidinostat plus R-CHOP was safe and effective for previously untreated diffuse large B-cell lymphoma expressing MYC and BCL-2.

A brentuximab vedotin-containing regimen led to “unprecedented” progression-free survival improvements in patients with advanced classical Hodgkin lymphoma.

This marks the only CAR T-cell therapy approved by the FDA for 4 subtypes of non-Hodgkin lymphoma.

Second-line venetoclax may lead to monthly cost savings vs second-line BTK inhibitor for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Lisocabtagene maraleucel was approved by the FDA to treat adults with relapsed/refractory follicular lymphoma who were treated with 2 or more prior lines of systemic therapy.

A nurse-driven, verbal workflow to place tocilizumab orders contributed to safer and more effective delivery of tocilizumab for cytokine release syndrome.

Patients with untreated mantle cell lymphoma treated with acalabrutinib plus bendamustine and rituximab had significant improvements in progression-free survival compared with bendamustine and rituximab alone.

Treatment for relapsed or refractory diffuse large B-cell lymphoma with brentuximab vedotin, lenalidomide, and rituximab contributed to an improvement in overall survival vs lenalidomide/rituximab/placebo.

The FDA approved zanubrutinib plus obinutuzumab for the treatment of patients with relapsed or refractory follicular lymphoma after receiving 2 or more lines of systemic therapy.

Liso-cel may be an effective treatment option for relapsed/refractory mantle cell lymphoma, including those with high-risk features who have limited treatment options.

The FDA granted an orphan drug designation to soquelitinib for potential use in T-cell lymphoma.

Bispecific antibodies that engage T cells are an effective treatment modality in relapsed/refractory disease and are an important new treatment for relapsed large B-cell lymphoma.

A fast track designation has been granted by the FDA to the novel BTK degrader, NX-5948, for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with at least two lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.

The median overall survival among those treated with tisagenlecleucel was not reached, and the 36-month overall survival rate was 82%.

High disease burden may be associated with more bridging therapy use and contribute to worse outcomes, according to investigators.

Most biomarkers in subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p) derived benefit from zanubrutinib vs bendamustine plus rituximab.

At a median 39 months of follow-up, zanubrutinib reduced the risk of disease progression by 32% compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.